Twist Bioscience Co. (NASDAQ:TWST) Shares Sold by E Fund Management Co. Ltd.

E Fund Management Co. Ltd. trimmed its holdings in shares of Twist Bioscience Co. (NASDAQ:TWST) by 45.7% during the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 6,261 shares of the company’s stock after selling 5,274 shares during the period. E Fund Management Co. Ltd.’s holdings in Twist Bioscience were worth $309,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of the business. Artisan Partners Limited Partnership lifted its position in Twist Bioscience by 111.3% during the fourth quarter. Artisan Partners Limited Partnership now owns 3,723,305 shares of the company’s stock valued at $137,241,000 after buying an additional 1,961,621 shares in the last quarter. Dimensional Fund Advisors LP lifted its position in shares of Twist Bioscience by 29.0% during the fourth quarter. Dimensional Fund Advisors LP now owns 1,267,708 shares of the company’s stock worth $46,732,000 after purchasing an additional 284,884 shares in the last quarter. Baillie Gifford & Co. lifted its position in shares of Twist Bioscience by 12.1% during the first quarter. Baillie Gifford & Co. now owns 1,227,528 shares of the company’s stock worth $42,116,000 after purchasing an additional 132,770 shares in the last quarter. Charles Schwab Investment Management Inc. lifted its position in shares of Twist Bioscience by 1.3% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 448,232 shares of the company’s stock worth $16,522,000 after purchasing an additional 5,728 shares in the last quarter. Finally, Victory Capital Management Inc. lifted its position in shares of Twist Bioscience by 4,133.1% during the second quarter. Victory Capital Management Inc. now owns 308,171 shares of the company’s stock worth $15,187,000 after purchasing an additional 300,891 shares in the last quarter.

Analyst Upgrades and Downgrades

A number of research analysts have recently commented on TWST shares. Guggenheim started coverage on shares of Twist Bioscience in a research report on Tuesday, June 4th. They set a “buy” rating and a $53.00 target price on the stock. JPMorgan Chase & Co. boosted their target price on shares of Twist Bioscience from $28.00 to $35.00 and gave the stock an “underweight” rating in a research report on Monday, August 5th. Barclays reduced their target price on shares of Twist Bioscience from $60.00 to $55.00 and set an “overweight” rating on the stock in a research report on Monday, August 5th. TD Cowen boosted their target price on shares of Twist Bioscience from $55.00 to $65.00 and gave the stock a “buy” rating in a research report on Thursday, June 13th. Finally, Robert W. Baird lifted their price target on shares of Twist Bioscience from $40.00 to $46.00 and gave the stock an “outperform” rating in a research note on Monday, August 5th. One analyst has rated the stock with a sell rating and eight have given a buy rating to the company. According to data from MarketBeat, Twist Bioscience currently has a consensus rating of “Moderate Buy” and an average target price of $48.22.

Twist Bioscience Trading Down 1.4 %

Shares of NASDAQ:TWST opened at $47.02 on Thursday. Twist Bioscience Co. has a 12-month low of $14.42 and a 12-month high of $60.90. The company has a fifty day simple moving average of $47.50 and a 200 day simple moving average of $42.91. The firm has a market cap of $2.75 billion, a PE ratio of -13.99 and a beta of 1.76.

Twist Bioscience (NASDAQ:TWST) last released its earnings results on Friday, August 2nd. The company reported ($1.47) earnings per share for the quarter, missing the consensus estimate of ($0.76) by ($0.71). Twist Bioscience had a negative net margin of 74.63% and a negative return on equity of 32.17%. The business had revenue of $81.50 million for the quarter, compared to the consensus estimate of $77.40 million. During the same quarter in the previous year, the firm earned ($1.01) EPS. The firm’s revenue for the quarter was up 27.7% on a year-over-year basis. As a group, equities research analysts forecast that Twist Bioscience Co. will post -3.13 EPS for the current fiscal year.

Insider Buying and Selling at Twist Bioscience

In other Twist Bioscience news, SVP Paula Green sold 1,137 shares of the business’s stock in a transaction on Monday, August 5th. The shares were sold at an average price of $39.93, for a total transaction of $45,400.41. Following the completion of the sale, the senior vice president now owns 88,837 shares in the company, valued at $3,547,261.41. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. In other news, CEO Emily M. Leproust sold 1,114 shares of the company’s stock in a transaction dated Tuesday, July 2nd. The shares were sold at an average price of $48.00, for a total transaction of $53,472.00. Following the completion of the transaction, the chief executive officer now owns 504,732 shares in the company, valued at $24,227,136. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, SVP Paula Green sold 1,137 shares of the company’s stock in a transaction dated Monday, August 5th. The stock was sold at an average price of $39.93, for a total transaction of $45,400.41. Following the transaction, the senior vice president now owns 88,837 shares of the company’s stock, valued at approximately $3,547,261.41. The disclosure for this sale can be found here. Insiders sold a total of 15,125 shares of company stock worth $664,784 over the last 90 days. Insiders own 3.92% of the company’s stock.

About Twist Bioscience

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.